Nat. Biotechnol. 31, 181–183 (2013); published online 7 March 2013; corrected after print 3 May 2013
In the version of this article initially published, the experimental drug nivolumab was incorrectly designated BMS-936588. The correct designation is BMS-936558. The error has been corrected in the HTML and PDF versions of the article.
Additional information
The online version of the original article can be found at 10.1038/nbt0313-181
Rights and permissions
About this article
Cite this article
Sheridan, C. Correction: Corrigendum: Industry pursues co-stimulatory receptor immunomodulators to treat cancer. Nat Biotechnol 31, 566 (2013). https://doi.org/10.1038/nbt0613-565g
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0613-565g
